R&D Longevity studies in life sciences today Longevity has been discussed for a while now in the context of life sciences and pharma - we take a look at what's new now with Anat Naschitz.
Patients Why biohackers are ditching vague health metrics Precision diagnostics enable targeted therapeutics.
R&D Why everyone should care about longevity, with Boyang Wang In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Boyang Wang, the founder of Immortal Dragons.
R&D Longevity is not a consumer trend, but a pipeline strategy p... Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.
R&D The secrets of the secretome, with Hans Keirstead Immunis CEO Hans Keirstead explains why his company thinks the immune system is key to tackling healthspan and longevity.
R&D The frontier of 3D biofabrication in the race for healthy lo... pharmaphorum in conversation with Immortal Dragons and Frontier Bio about 3D tissue biofabrication and the race for healthy longevity.
News Sobi adds rare lymphoma drug with $580m Innate tie-up Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
